Page 60 - Haematologica June

M. Krevvata et al.
Table 1. Clinical characteristics of the patients with acute myeloid leukemia.
Patient Age ID (year)
2678 32
1532 69 1907 82 2022 63 3876 49 2955 69 2120 68 3328 68 3339 29
1780 65 559 35 690 46 1587 70 3526 34 3219 55 3198 76 3119 52 2810 76 2323 75 2589 65 3094 79 3227 65 3229 68 3221 65 2012 65 3406 66 3568 76 3769 35 1902 43 2711 44 1658 70 3516 25 2141 52 1526 78 2943 65 1750 63 1919 27 3368 65 3779 60 1245 58 2017 64 2293 52 1926 58 1956 52 2093 58 2266 56 2522 52 2623 58 3216 51
3254 63 3965 55 3370 65 1731 76
Sex FAB classification
M AML - myeloid sarcoma
M AML with 11q23 abnormalities M AML with 11q23 abnormalities F AML with 11q23 abnormalities M AML with inv16(p13;q22) or t F AML with inv16(p13;q22) or t F AML with inv16(p13;q22) or t F Secondary
M AML with inv16(p13;q22) or t
M AML with inv16(p13;q22) or t M AML with inv16(p13;q22) or t F AML with inv16(p13;q22) or t M AML with t(8;21)(q22;q22)
M AML with t(8;21)(q22;q22)
M AML-MLD hx prior MDS/MPN F AML-MLD hx prior MDS/MPN M AML-MLD no prior MDS or MPN M AML-MLD with prior MDS
M AML-MLD with prior MDS M AML-MLD with prior MDS F AML-MLD with prior MDS M AML-MLD with prior MDS F AML-MLD with prior MDS M AML-MLD with prior MDS M AML-MLD with prior MPN M AML-MLD with prior MPN
NA Biphenotypic
M CML (myeloid blast crisis) M M0
M M1
F M1
F M1
M M1
M M1
M M1
M M3 (APML)
F M4
M M4
M M4
M M4
M M4
M M4
M M4
F M4
F M4
M M4
M M4
F M4
F M4
M M4 M M4 M M4 M M5
WBC BM/PB
0.0723 PB
0.1375 PB 0.115 PB 0.0342 PB 0.1136 PB 0.0797 PB 0.0145 BM 0.0218 PB 0.0099 BM
0.0269 PB 0.15 BM 0.1293 PB 0.1709 PB 0.0315 PB 0.14 PB 0.1446 PB 0.0315 PB 0.1536 PB 0.0753 PB 0.1164 PB 0.0571 PB 0.0793 PB ND PB 0.1616 PB 0.1596 PB 0.1704 PB 0.2457 PB 0.5717 PB ND PB 0.326 PB 0.0962 PB 0.3045 PB 0.0454 PB 0.0713 PB 0.1928 PB 0.1003 PB 0.1457 PB 0.2516 PB 0.1845 PB 0.1364 PB 0.0766 PB 0.1952 PB 0.0871 PB 0.1391 PB 0.079 PB 0.314 PB 0.113 PB 0.2878 PB 0.1038 PB
0.1595 PB 0.0577 PB 0.2419 PB 0.129 PB
Disease status
NA
Treatment related
De novo
Treatment related
De novo
De novo
De novo Treatment related De novo
Cytogenetics FLT3 Normal NA
t(11;22)(q23;q13) WT t(9;11), der(13;14) NA t(11;16)(q23;p13.3) WT
del(12), ins(14;12), inv(16),+21 D835
46,XX,inv(16)(p13.2q22) WT
inv(16)(p13.2q22) WT
inv(16)(p13.1q22)/47,idem,+8 NA
46,XY,del(7)(q32),inv(16), WT (p13.3q22)/47,idem+22/46,XY
NPM Blasts % Blasts % Engrafter Engrafter
(PB) (BM) in NSG
in NSG-S
ND
MSC MSC ND MSC ND MSC MSC MSC
MSC MSC MSC N ND ND MSC ND N ND ND ND ND ND MSC ND MSC MSC N MSC MSC MSC ND ND MSC ND MSC MSC MSC MSC ND ND ND ND ND ND ND ND ND MSC
MSC MSC ND MSC
De novo De novo De novo
Treatment related add(20)(q11.2) D835 Denovo ND WT
NA NA
NA 64 NA 75 NA 26 WT NA WT 72 NA NA NA 50 WT NA
NA 11 NA NA NA 61 NA 91 NA 67 WT 10 WT 21
MUT 24 WT 40 NA 63 WT NA NA 4 NA 89 NA NA NA 89 NA NA WT 77 WT NA NA 66 NA 41 WT NA NA NA WT 91 NA 83 NA 78
MUT 94 NA NA NA 83
MUT 74 WT NA NA NA NA NA NA 87 NA 89 NA 51 NA 60 NA 90 NA NA NA NA NA 50
WT NA
WT 89 MUT 74 NA NA
NA MSC
NA N NA N NA N NA N NA N 60 N NA MSC 27 N
NA N 77 N NA N NA N 68 N NA N 60 MSC 32 MSC NA N NA N NA N NA N NA MSC NA MSC NA MSC NA MSC 70 MSC NA MSC NA N 90 N NA N NA N NA N NA MSC NA MSC NA MSC NA N NA N 90 N NA N NA N 51 N NA N NA MSC NA MSC NA MSC 90 MSC NA MSC NA MSC NA MSC
NA MSC NA MSC 90 MSC NA N
46,XY,inv(16)(p13.1q22) WT 47,XY,inv(16)(p13.3q22),+22/48,XY,idem,+9NA
46,XX,inv(16)(p13.3q22)/47,XX,idem+8 NA Treatment related t(8;21)(q22;q22),del(13)(q12q22) WT NA t(8;21)(q22;q22) NA De novo del(7)(p11.2)/46,XY WT Denovo NA ITD De novo Normal WT
Relapsed Relapsed NA Refractory Relapsed De novo De novo NA
NA Refractory De novo De novo NA Relapsed De novo De novo
47,XY,+11[18]/46,XY[2] ITD Normal NA Normal WT Normal WT Normal WT Complex WT del(20)(q11.2q13.1) WT
Complex ITD t(9;22)(q34;q11.2)/48,idem,+8,+19 NA NA NA
Normal ITD
Normal ITD inv(9)(p12q13) ITD NA ITD Normal ITD Normal ITD
NA t(15;17) NA
Relapsed
De novo De novo De novo Untreated De novo Relapsed De novo De novo De novo Refractory Relapsed
NA NA NA WT NA ITD
normal ITD NA NA Normal ITD
NA ITD 47,XX,+8/46,XX ITD Normal ITD Normal ITD Complex ITD NA ITD Relapsed t(3;3)(q21;q26),del(7) WT
962
(p13),del(17)(p12),-21
De novo Complex WT NA Normal ITD De novo Normal WT De novo Normal WT
haematologica | 2018; 103(6)
continued on next page